ENThe short answer to what countries use stem cell therapy: blood-forming stem cell transplants are done wherever a developed transplant service exists, while other cell treatments are allowed in some countries only as licensed medicines or in trials, and sold elsewhere as a private service. Anyone asking is usually weighing an offer: a clinic abroad has quoted a price and promised improvement. Is it a serious address, or a country where nobody asks questions?
The honest answer starts with the procedure’s legal category, not the country, so categories come first here. Which diseases cells treat with proven benefit is covered in stem cell treatment: what is proven and what is not.
Two different things share one name
One name covers recognised treatment and experiments sold as treatment. Recognised above all is the transplantation of blood-forming (haematopoietic) stem cells from bone marrow or blood, a standard hospital treatment for leukaemia, lymphoma and other blood diseases, including inherited ones such as thalassaemia and sickle cell disease. The World Health Organization lists these cells among the cell, tissue and gene therapy products of demonstrated effectiveness.
A second, much smaller group are licensed cell and gene medicines, approved after clinical trials for narrow indications. In the EU these include several CAR-T products for certain blood cancers and Holoclar: cells taken from the edge of the patient’s own cornea, including stem cells, and grown in a laboratory, for adults lacking corneal stem cells after an eye burn. They are prescription medicines, not a price-list service.
Everything else — injections of «mesenchymal», fat-derived, umbilical or animal cells for arthritis, autism, diabetes, multiple sclerosis or «anti-ageing» — fits neither group and in most countries is an experiment sold as treatment. The European Medicines Agency warns of serious risks for little or no benefit.
Countries where the rules are strict
The answer to what countries use stem cell therapy under strict rules is the EU, Germany included, the US, Canada, the UK, Australia and Japan. In the EU, substantially manipulated cells, or cells given for a different function than in the body, count as advanced therapy medicinal products, governed by Regulation 1394/2007. They are legal only with a marketing authorisation, in an authorised trial or under a national hospital exemption for a product made non-routinely for one patient, which in Germany the Paul Ehrlich Institute grants under section 4b of the Medicinal Products Act (its FAQ on advanced therapies).
The US, Canada, the UK and Australia have comparable systems, each with its own regulator. The US FDA says stem cell products generally need its approval and otherwise may only be given in trials it oversees. In Japan, regenerative products assessed by the PMDA can get conditional, time-limited approval, within which the manufacturer must gather data and reapply. A separate law lets Japanese clinics offer cell methods whose safety and efficacy are not yet established, after a certified committee reviews the plan and the health ministry receives it. Hence Japanese offers sometimes look broader than European ones.
In practice, a doctor in a strictly regulated country cannot simply offer cells for an unapproved condition: a serious clinic offers an authorised trial, if one is running and the patient qualifies, or says no. The European Medicines Agency advises checking the approved indication.
Countries where they are sold freely
Cell injections are sold freely where they count as a private service rather than a medicine; a whole branch of medical tourism runs on this, with one protocol for dozens of unrelated diagnoses. We name no countries: the warning signs look the same everywhere — treatment «for any diagnosis», payment in advance, no written protocol, no follow-up, testimonials instead of published results. The Paul Ehrlich Institute adds unfounded cure promises and paid «experimental therapies» outside approved trials.
The risks go beyond money. The European Medicines Agency reports serious, sometimes fatal side effects of unproven cell treatments: infections, immune reactions, tumour formation, vision loss, bleeding in the brain; the FDA adds reactions at collection and injection sites and cells moving elsewhere in the body. And months are lost in which a proven treatment could have begun.
How to check a specific offer
Five questions, put to the clinic in writing, test an offer. What exactly is injected: which cells, from where, processed how? On what legal basis? Under which authorisation or trial number? What published evidence exists for this diagnosis? And what happens if there is no improvement?
A registered trial has a number in a public register, such as the EU’s, Germany’s DRKS or ClinicalTrials.gov, that shows who runs it and where it recruits. Licensed medicines are listed by the European Medicines Agency and, for Germany, the Paul Ehrlich Institute. A treating doctor names both without hesitation.
A plausible «no» from a German clinic is specific: no medicine is licensed for your diagnosis, no suitable trial is recruiting, nobody will inject cells outside these routes, and here is the alternative. Such a refusal is a good sign: the clinic follows the rules and sells nothing it cannot justify. See Is stem cell therapy legal in Germany?
Where Germany fits in
Germany is strictly regulated but has two worlds. In one, haematology and transplant departments of university and other large hospitals transplant blood-forming stem cells, run registered cell therapy trials and use a few licensed cell products. In the other, private clinics offer cell procedures outside all this. Do not confuse them: EU regulators warn that unregulated cell products are sold inside the EU too.
Three questions tell them apart on the ground. Is the appointment with haematology, oncology or transplantation at a large hospital, or with a private «regenerative medicine» practice? What is the doctor’s specialty? Is the treatment documented as a trial, with a number, written consent and a follow-up plan? Both kinds are described on stem cell clinics in Germany, the bill on the cost of stem cell treatment in Germany page.
Frequently asked questions
What country is best for stem cell therapy?
No single country is best; what matters is whether your diagnosis has a recognised treatment or licensed product, and who answers for it. Choose a country where a regulator oversees cell products and unapproved use happens only in registered trials. A clinic promising results for any diagnosis, with no authorisation or trial number, is a poor choice anywhere.
Where is the best place in Europe for stem cell therapy?
There is no ranking of European countries: within the European Union the basic rules for cell products are shared. Centres differ in experience with your disease and access to trials. So first check public registers for a licensed product or a trial recruiting patients with your diagnosis, then choose the clinic that works with it.
Is it worth travelling to another country if a German clinic said no?
Only if it offers what Germany could not: a medicine licensed for your diagnosis or an authorised trial that will take you. If a German clinic refused because neither exists, a yes elsewhere adds no evidence. Put the five questions to the new offer and show the answers to an independent specialist; regulators also advise a second opinion.
How AlenMed helps compare options
AlenMed first establishes whether there is anything to travel for: it collects and translates the records and obtains a written opinion from a specialist in the field in Germany on whether cell-based treatment is realistic for this diagnosis at all. A clinic estimate and visa invitation follow only if the trip has a medical purpose.
Even a negative answer comes in writing, in a language the patient reads, with the reasoning and a named alternative suited to the diagnosis.
This material is for information only and is not an offer. Treatment decisions, including on cell therapy, are made by a doctor in person.